ABL1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 14.29% of myeloid sarcoma patients [2].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for myeloid sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and myeloid sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is altered in 14.29% of myeloid sarcoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].